Whicher J T, Ritchie R F, Johnson A M, Baudner S, Bienvenu J, Blirup-Jensen S, Carlstrom A, Dati F, Ward A M, Svendsen P J
Institute for Cancer Studies, St. James's University Hospital, Leeds, UK.
Clin Chem. 1994 Jun;40(6):934-8.
Quality-control surveys in recent years, in various parts of the world, have shown poor between-laboratory agreement for measurements of plasma proteins. Despite the existence of international reference materials distributed by the World Health Organization, standards produced by diagnostics manufacturers and professional organizations differ significantly in their ascribed values. The reasons for this are complex but include poor availability of the primary materials, confusion about their use, and the fact that their turbidity on reconstitution precludes their use in modern optical immunoassays. This unfortunate situation led to an important initiative to produce sufficient quantities of a widely available, optically clear secondary reference material for plasma proteins that could be used worldwide by manufacturers, professional organizations, and laboratories. Here we present an overview on how the laboratory community, including manufacturers, clinical laboratories, professional societies, and regulators, has reached what we consider is a successful conclusion to a difficult problem.
近年来,世界各地的质量控制调查表明,实验室之间在血浆蛋白测量方面的一致性较差。尽管世界卫生组织分发了国际参考物质,但诊断制造商和专业组织生产的标准品在其规定值上存在显著差异。造成这种情况的原因很复杂,包括主要材料供应不足、对其使用的困惑,以及它们复溶后的浊度使其无法用于现代光学免疫分析。这种不幸的情况促使人们采取一项重要举措,即生产足够数量的、广泛可用的、光学清澈的血浆蛋白二级参考物质,供制造商、专业组织和实验室在全球范围内使用。在此,我们概述了包括制造商、临床实验室、专业协会和监管机构在内的实验室界是如何成功解决这一难题的。